Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by Biotech777on Apr 08, 2014 9:30am
180 Views
Post# 22423904

RE:Is RVX-208 lumped in with Statins by BP

RE:Is RVX-208 lumped in with Statins by BP
While the only fix for a 90% blockage is bypass or revascularization, a 90% blockage rarely causes an ischemic event acutely. The lesions that you are worried about are typically the 40% lesions where there is no reduction in blood flow due to positive arterial remodeling. The mechanism of action for RVX and other apoa-1 or direct lipid binding drugs is really stabilization of a certain type of plaque. There is no question that a drug tha reduces the risk of a primary or secondary ischemic event in the acute coronary patient is a blockbuster. The open questions for RVX are whether they can duplicate the previous MACE numbers and whether they have to limit their inclusuion criteria to crestor and high CRP. The latter being a problem for me.

Regardless of how we got here, I am glad they are finally off of plaque regression as a surrogate endpoint. Now a days, I tend to only look at companies in this space that are focused on plaque stabilization versus plaque regression at least from an investment standpoint.
Bullboard Posts